Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053209 | 0.86 | CYP2C19 (0.44) | POLBTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5053272 | 0.76 | TAAR1 (0.36) | TAAR1 | |
| SCHEMBL7611344 | 0.75 | MMP12 (0.43) | TDP1RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL27406652 | 0.72 | TAAR1 (0.50) | POLBTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27840098 | 0.72 | MMP12 (0.51) | POLBTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27820829 | 0.72 | MMP12 (0.51) | POLBTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3861759 | 0.72 | MMP12 (0.51) | POLBTDP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5051336 | 0.71 | TBXAS1 (0.48) | SMN1; SMN2HPGDLMNA | |
| SCHEMBL5058011 | 0.71 | TAAR1 (0.34) | POLBTAAR1 | |
| SCHEMBL1176719 | 0.71 | CYP2C19 (0.49) | POLBTDP1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |